VERU Stock Forecast 2025-2026
Distance to VERU Price Targets
VERU Price Momentum
🤔 Considering Veru (VERU)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest VERU Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, VERU has a bullish consensus with a median price target of $3.00 (ranging from $3.00 to $4.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $0.48, the median forecast implies a 525.0% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Yi Chen at HC Wainwright & Co., suggesting a 525.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VERU Analyst Ratings
VERU Price Target Range
Latest VERU Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VERU.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 2, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Dec 20, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| Nov 5, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $5.00 |
| May 14, 2024 | B. Riley Securities | William Woods | Buy | Initiates | $5.00 |
| May 13, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $3.00 |
| May 6, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $3.00 |
| Apr 15, 2024 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $5.00 |
| Mar 28, 2024 | Raymond James | Gary Nachman | Outperform | Initiates | $3.00 |
| Feb 8, 2024 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.00 |
| Sep 27, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.00 |
| Jun 7, 2023 | Jefferies | Chris Howerton | Hold | Upgrade | $1.00 |
| May 15, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $2.00 |
| May 8, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Apr 12, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $6.00 |
| Apr 6, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $6.00 |
| Mar 15, 2023 | Oppenheimer | Leland Gershell | Outperform | Maintains | $9.00 |
| Feb 14, 2023 | Oppenheimer | Leland Gershell | Outperform | Maintains | $14.00 |
| Feb 10, 2023 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $14.00 |
| Dec 7, 2022 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $18.00 |
| Dec 5, 2022 | Cantor Fitzgerald | Brandon Folkes | Overweight | Maintains | $22.00 |
Veru Inc. (VERU) Competitors
The following stocks are similar to Veru based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Veru Inc. (VERU) Financial Data
Veru Inc. has a market capitalization of $70.91M with a P/E ratio of -1.7x. The company generates $16.89M in trailing twelve-month revenue with a -227.8% profit margin.
Revenue growth is -100.0% quarter-over-quarter, while maintaining an operating margin of -242.6% and return on equity of -81.7%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Veru Inc. (VERU) Business Model
About Veru Inc.
Develops novel medicines for oncology and infectious diseases.
Veru Inc. operates as a biopharmaceutical company focusing on developing and commercializing innovative therapies. The company generates revenue through the development of proprietary pharmaceuticals and strategic partnerships, which may include licensing agreements for additional drug candidates.
Based in Miami, Florida, Veru is particularly focused on addressing unmet needs in oncology, especially for prostate and breast cancer, while also expanding its portfolio in infectious diseases. The company's emphasis on strategic partnerships enhances its research and development capabilities, positioning it as a significant player in the biopharmaceutical industry.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
210
CEO
Dr. Mitchell S. Steiner F.A.C.S., M.D.
Country
United States
IPO Year
1990
Website
verupharma.comVeru Inc. (VERU) Latest News & Analysis
Veru (VERU) has formed a hammer chart pattern, suggesting support after recent losses. Upward revisions in earnings estimates may indicate a potential trend reversal.
The hammer chart pattern suggests potential support for Veru (VERU), while rising earnings estimates may signal a trend reversal, indicating possible upside for investors.
Veru (VERU) appears to be in oversold territory, with Wall Street analysts revising earnings estimates higher, suggesting potential for a trend reversal.
Veru (VERU) may be positioned for recovery as it is oversold and analysts are raising earnings estimates, signaling potential upward momentum and investment opportunities.
Veru Inc (VERU) Q1 2025 Earnings Call Transcript
1 month agoVeru Inc (NASDAQ:VERU) will hold its Q1 2025 Earnings Conference Call on February 13, 2025, at 8:00 AM ET, featuring key executives including CEO Mitchell Steiner and CFO Michelle Greco.
The earnings call on February 13, 2025, will provide insights into Veru Inc's financial performance and strategic direction, influencing investor sentiment and stock valuation.
The company announced positive Phase 2b QUALITY study results for enobosarm + semaglutide, achieving key endpoints in lean mass preservation, fat loss, and physical function. The study will continue as recommended.
Positive Phase 2b results and ongoing study support potential for enobosarm + semaglutide, indicating a promising drug pipeline that could enhance revenue and market position.
Veru Inc. (VERU) shares are falling after the company announced topline results from its Phase 2b QUALITY study of enobosarm for weight reduction.
Veru Inc.'s stock decline signals potential setbacks in its drug development, affecting investor confidence and future revenue projections.
Enobosarm treatment significantly reduced lean mass loss in subjects using WEGOVY (p=0.002), with patients on Enobosarm losing 71% less lean mass than those on WEGOVY alone.
The significant reduction in lean mass loss with Enobosarm suggests potential for better treatment outcomes, enhancing its market appeal and possibly increasing company valuation.
Frequently Asked Questions About VERU Stock
What is Veru Inc.'s (VERU) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Veru Inc. (VERU) has a median price target of $3.00. The highest price target is $4.00 and the lowest is $3.00.
Is VERU stock a good investment in 2025?
According to current analyst ratings, VERU has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.48. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VERU stock?
Wall Street analysts predict VERU stock could reach $3.00 in the next 12 months. This represents a 525.0% increase from the current price of $0.48. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Veru Inc.'s business model?
Veru Inc. operates as a biopharmaceutical company focusing on developing and commercializing innovative therapies. The company generates revenue through the development of proprietary pharmaceuticals and strategic partnerships, which may include licensing agreements for additional drug candidates.
What is the highest forecasted price for VERU Veru Inc.?
The highest price target for VERU is $4.00 from at , which represents a 733.3% increase from the current price of $0.48.
What is the lowest forecasted price for VERU Veru Inc.?
The lowest price target for VERU is $3.00 from Yi Chen at HC Wainwright & Co., which represents a 525.0% increase from the current price of $0.48.
What is the overall VERU consensus from analysts for Veru Inc.?
The overall analyst consensus for VERU is bullish. Out of 8 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $3.00.
How accurate are VERU stock price projections?
Stock price projections, including those for Veru Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
